Unicycive Therapeutics Inc
Save
47.96M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Similar securities

Based on sector and market capitalization

Report issue